Published • loading... • Updated
Oxford University Cancer Prevention Vaccine Breakthrough
The INTERCEPT-Lynch study will test whether Moderna’s vaccine can trigger immune responses against early cancer changes in people with Lynch syndrome.
- On Tuesday, June 9, 2026, the University of Oxford and Moderna announced the Intercept-Lynch trial, a cancer-prevention vaccine study targeting patients at high risk of bowel and ovarian cancer.
- Lynch syndrome affects around 175,000 people in England and increases lifetime bowel cancer risk by around 80 per cent, yet only 5 per cent of carriers are aware they have the condition.
- Professor David Church, lead investigator at Oxford, said the vaccine aims to "train the immune system" to recognize abnormalities, acting as "an instruction manual" for attacking pre-cancerous cells.
- David Berman, Moderna's chief development officer, said the company aims to apply mRNA technology earlier in the patient journey to "harness the immune system when it can have the greatest impact."
- Experts believe the approach could eventually be adapted for other cancer types, while a second study phase including multiple centers across the UK is expected to begin in 2027.
Insights by Ground AI
15 Articles
15 Articles
Get Surrey+2 Reposted by 2 other sources
New vaccine against cancer developed in UK and will be tested this summer
The vaccine could help thousands of people with a faulty gene that makes them vulnerable to cancer
·Guildford, United Kingdom
Read Full Article
Oxford MailReposted by 
thisisoxfordshire.co.uk
thisisoxfordshire.co.ukOxford University cancer prevention vaccine breakthrough
A cancer prevention vaccine for people at high risk of bowel and ovarian cancer has been developed by the University of Oxford with the…
·Oxford, United Kingdom
Read Full Article
Hastings Tribune+2 Reposted by 2 other sources
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%
·Nebraska, United States
Read Full Article
Coverage Details
Total News Sources15
Leaning Left4Leaning Right2Center5Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 36%
C 46%
R 18%
Factuality
To view factuality data please Upgrade to Premium
